查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
数位计量吸入器市场：2023年至2028年预测
市场调查报告书
商品编码
1410145

数位计量吸入器市场：2023年至2028年预测

Digital Dose Inhaler Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计数位计量吸入器市场在预测期内将以 8.64% 的复合年增长率成长。

数位计量吸入器是一种紧凑的便携式设备，其中含有旨在缓解呼吸问题的药物。透过向肺部输送精确剂量的药物，它可以有效治疗气喘、慢性阻塞性肺病（COPD）和其他呼吸困难等呼吸系统疾病。

慢性呼吸道疾病的增加将推动数位给药市场的成长。

数位计量吸入器广泛用于慢性呼吸道疾病的治疗，因为它们能够将精确剂量的药物直接输送到肺部，从而有效地控制症状并改善治疗结果。流感和呼吸道融合细胞病毒（RSV）等病毒感染疾病的增加，加上呼吸道疾病盛行率的上升以及污染问题，导致对数位计量吸入器的需求激增。根据美国疾病管制与预防美国的数据，2022 年 18 岁以上成年人中心绞痛的盛行率为 1.6%，而 2021 年为 1.5%。这显示过去两年成年人心绞痛的盛行率略有上升。

对研发活动的投资正在推动数位计量吸入器产业的发展。

製药和医疗保健技术公司正在透过整合数位功能、智慧感测器和先进的连接来改善吸入器技术的研发投资。这些发展使得给药更加准确、患者医嘱遵从性提高以及即时监测能力得以实现。此外，研究和开发工作正在促进个人化医疗解决方案的创建，根据患者的个别需求量身定制治疗计划并优化疾病管理。例如，瑞士製药巨头罗氏将研发支出从前一年的133亿美元大幅增加至2022年的147亿美元。这些策略投资正在推动数位计量吸入器市场的成长。

技术进步推动了数位计量吸入器市场的成长。

吸入器市场的尖端创新透过增强药物输送和监测能力，显着提高了患者的准确性和易用性。智慧感测器透过提供吸入器使用情况的即时资料，使患者和医疗保健提供者能够追踪医嘱遵从性并调整治疗计划，从而推动了数位计量吸入器市场的需求。例如，药物传输专家 Aptar Pharma 于 2022 年 2 月推出了 HeroTracker Sense。 HeroTracker Sense 是一种数位呼吸健康解决方案，可将标准计量吸入器 (pMDI) 转变为智慧连线健诊设备，从而能够即时监控药物使用情况，并提供有价值的信息，以改善呼吸健康管理。

预计亚太地区将主导数位计量吸入器市场。

亚太地区将占据重要的市场占有率，因为气喘发作的日益流行正在为采用数位计量吸入器创造有利的环境。例如，根据澳洲统计局的数据，2020 年至 2021 年间，约有 10.7% 的总人口（即 270 万人）患有气喘。政府提高医疗设备生产的措施也推动了市场成长。例如，印度政府于2023年4月核准的国家医疗设备政策旨在促进印度医疗设备产业的结构性扩张，并将该国打造为全球医疗设备製造领域的领导者。

隐私问题可能会限制数位计量吸入器市场的成长。

从患者和医疗机构的角度来看，将资料收集和传输功能整合到数位计量吸入器中引发了重大的隐私和安全问题。这些担忧围绕着敏感健康资料的潜在漏洞，这反过来可能会影响采用这些先进吸入器技术的意愿和接受度。患者可能会犹豫是否使用此类设备，而不保证其个人健康资讯将受到保护，而医疗保健提供者和组织可能会犹豫是否要完全采用此类创新的吸入器解决方案。可能需要强有力的资料保护措施。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
  • 产业价值链分析

第五章数位计量吸入器市场：依产品

  • 介绍
  • 定量吸入器 (MDI)
  • 干粉吸入器 (DPI)

第六章数位计量吸入器市场：按类型

  • 介绍
  • 品牌药品
  • 学名药

第七章数位计量吸入器市场：依适应症分类

  • 介绍
  • 气喘
  • 慢性阻塞性肺病（COPD）
  • 其他的

第八章数字计量吸入器市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 新兴企业和市场盈利
  • 合併、收购、协议和合作
  • 供应商竞赛矩阵

第十章 公司简介

  • 3M Company
  • AstraZeneca Plc
  • Aptar
  • Novartis AG
  • Propeller Health
  • Sensirion AG
  • Opko Health, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • BEXIMCO Pharmaceuticals
  • GlaxoSmithKline Plc
简介目录
Product Code: KSI061615814

The digital dose inhaler market is estimated to grow at a CAGR of 8.64% during the forecast period.

A digital dose inhaler is a compact, portable device containing medicine designed to alleviate breathing issues. By delivering a precise dosage of medication into the lungs it effectively treats respiratory problems such as asthma, chronic obstructive pulmonary disease (COPD), and other breathing difficulties.

Growing chronic respiratory disease prevalence bolsters the digital dose market growth.

Digital dose inhalers are extensively used to treat chronic respiratory diseases due to their ability to deliver precise doses of medication directly into the lungs thereby effectively managing symptoms and improving treatment outcomes. The growing number of viral infections, such as influenza and respiratory syncytial virus (RSV) coupled with pollution problems are increasing the prevalence of respiratory conditions, thereby booming the digital dose inhalers demand. According to the Centers for Disease Control and Prevention, In the United States, the percentage of angina cases among adults aged 18 and over was 1.6% in 2022, compared to 1.5% in 2021. This indicates a slight increase in the prevalence of angina among the adult population between the two years.

Investments in R&D activities drive the digital dose inhaler industry.

Pharmaceutical companies and healthcare technology firms are improving their R&D investment in inhaler technology by incorporating digital features, smart sensors, and advanced connectivity. These developments result in more precise dosing, improved patient adherence, and real-time monitoring capabilities. Furthermore, R&D efforts are fostering the creation of personalized medicine solutions, tailoring treatment plans to individual patient needs, and optimizing disease management. For instance, Roche, the Swiss pharmaceutical giant, significantly increased its research and development (R&D) expenditure to $14.7 billion in 2022, marking a notable rise from the $13.3 billion spent in the previous year. Such strategic investments have propelled the digital dose inhaler market growth.

Technological advancements drive digital dose inhaler market growth.

The cutting-edge innovations in the inhaler market have significantly improved the precision and ease of use for patients by offering enhanced medication delivery and monitoring capabilities. The smart sensors provide real-time data on inhaler usage which enables patients and healthcare providers to track adherence and adjust treatment plans thereby promoting better disease management which has bolstered the digital dose inhaler market demand. For instance, in February 2022, Aptar Pharma, a specialist in drug delivery, services, introduced HeroTracker Sense, a digital respiratory health solution that transforms a standard metered dose inhaler (pMDI) into a smart connected healthcare device, enabling real-time monitoring of medication usage and providing valuable insights to improve respiratory health management

Asia-Pacific is expected to dominate the digital dose inhaler market.

Asia-Pacific will hold a significant market share due to the growing prevalence of asthma attacks thereby creating an environment conducive to digital dose inhaler adoption. For instance, according to the Australian Bureau of Statistics, from 2020 to 2021, approximately 10.7% of the total population, or 2.7 million individuals, were reported to have asthma. Also, supportive government initiatives to boost medical device production are additionally driving market growth. For instance, the National Medical Devices Policy, approved by the Indian government in April 2023, aims to foster a well-structured expansion of the medical device sector in India and to establish the country as a global leader in medical device manufacturing.

Privacy concerns may restrain the digital dose inhaler market growth.

The integration of data collection and transmission features in digital dose inhalers has brought forth significant concerns related to privacy and security, both from the perspective of patients and healthcare organizations. These anxieties revolve around the potential vulnerability of sensitive health data, and as a result, it may influence the level of willingness and acceptance in adopting these advanced inhaler technologies. Patients may be hesitant to use such devices without reassurance about safeguarding their personal health information, while healthcare providers and organizations may demand robust data protection measures before fully embracing these innovative inhaler solutions.

Key Developments

  • August 2022: Aptar Pharma, a leading provider of drug delivery and active material science solutions, completed the acquisition of Pharmaxis thereby acquiring global rights for the latter's "Orbital inhaler". The Orbital inhaler is an advanced device specifically developed for the delivery of high-payload dry powder directly to the lungs in clinical settings. This strategic move by Aptar Pharma strengthens its position in the field of drug delivery systems and expands its portfolio of innovative solutions for improving respiratory treatments.
  • December 2020: Berry Global, a leader in delivering innovative solutions for patient care in the healthcare market, achieved a significant milestone with its market-leading RS01 single-dose Dry Powder Inhaler (DPI) now equipped with built-in sensors and digital capabilities. As part of the newly-established Berry Global Healthcare, the advanced RS01X offers inhaler usage tracking and connects to a companion app, delivering personalized guidance to enhance patient adherence and improve inhaler technique.
  • May 2020: AstraZeneca formed a new partnership with Propeller Health to enhance its Symbicort inhaler by incorporating smart features. Propeller Health's connected platform will be integrated into AstraZeneca's Symbicort, enabling the digitization of asthma and chronic obstructive pulmonary disease (COPD) treatment. This collaboration revolutionized respiratory care, providing patients with valuable digital tools to monitor their inhaler usage and optimize their treatment plans.
  • January 2020: Aptar Pharma, renowned for its drug delivery systems and active packaging solutions, joined hands with Lupin Limited to introduce India's pioneering connected device for metered-dose inhalers (MDI) named ADHERO. This innovative add-on smart device serves as a breakthrough tool to support patients with chronic respiratory conditions, enabling them to monitor their MDI usage effectively and enhance adherence to prescribed therapies with advanced tracking capabilities, healthcare providers gain valuable insights to optimize treatment plans and achieve improved patient outcomes.

Segmentation

By Product

  • Metered Dose Inhaler (MDI)
  • Dry Powder Inhaler (DPI)

By Type

  • Branded Medication
  • Generic Medication

By Indication

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. DIGITAL DOSE INHALER MARKET, BY PRODUCT

  • 5.1. Introduction
  • 5.2. Metered Dose Inhaler (MDI)
  • 5.3. Dry Powder Inhaler (DPI)

6. DIGITAL DOSE INHALER MARKET, BY TYPE

  • 6.1. Introduction
  • 6.2. Branded Medication
  • 6.3. Generic Medication

7. DIGITAL DOSE INHALER MARKET, BY INDICATION

  • 7.1. Introduction
  • 7.2. Asthma
  • 7.3. Chronic Obstructive Pulmonary Disease (COPD)
  • 7.4. Others

8. DIGITAL DOSE INHALER MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. 3M Company
  • 10.2. AstraZeneca Plc
  • 10.3. Aptar
  • 10.4. Novartis AG
  • 10.5. Propeller Health
  • 10.6. Sensirion AG
  • 10.7. Opko Health, Inc.
  • 10.8. Teva Pharmaceutical Industries Ltd.
  • 10.9. BEXIMCO Pharmaceuticals
  • 10.10. GlaxoSmithKline Plc